“Persistence, Clinical and Economic Impact of Infliximab CT-P13 in Rheumatoid Arthritis, Psoriatic Arthropathy and Ankylosing Spondylitis Naïve and Switched Patients: After 5 Years of Follow-Up” (2022) Journal of Pharmacy and Nutrition Sciences, 12, pp. 74–79. doi:10.29169/1927-5951.2022.12.06.